Q-omics provides the consensus-scored MIR642A profile across patient tissues and cancer cell-line models. MIR642A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR642A is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, MIR642A RNA expression shows 10,018 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCS, HNSC, and LIHC as cancer lineages where MIR642A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR642A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR642A survival associations across molecular data types. MIR642A RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR642A RNA expression–survival associations across cancer types. High MIR642A expression shows unfavorable associations in UCS, ACC, KIRC, LGG, UCEC and LUSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR642A RNA expression.
This table summarizes MIR642A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR642A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR642A shows lower tumor expression in PRAD and ESCA and higher tumor expression in HNSC, KICH, PAAD and STAD. The HNSC box plot shows higher MIR642A RNA expression in tumor versus normal tissue (log2 FC = +0.410, t-test p < 0.001).
This table shows molecular features associated with MIR642A in patient tissues and cancer cell lines. In patient samples, MIR642A shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
